BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nash KL, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. J Cyst Fibros. 2008;7:252-257. [PMID: 18042441 DOI: 10.1016/j.jcf.2007.10.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, Rand EB, Shaked A, Abt PL. Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data: Liver Transplantation in Patients with Cystic Fibrosis. Liver Transpl 2011;17:243-50. [DOI: 10.1002/lt.22240] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
2 Gemery JM, Forauer AR, Silas AM, Hoffer EK. Hypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process. BMC Hematol 2016;16:3. [PMID: 26865982 DOI: 10.1186/s12878-016-0042-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
3 Lewindon PJ, Shepherd RW, Walsh MJ, Greer RM, Williamson R, Pereira TN, Frawley K, Bell SC, Smith JL, Ramm GA. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011;53:193-201. [DOI: 10.1002/hep.24014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
4 Rowland M, Gallagher CG, O'Laoide R, Canny G, Broderick A, Hayes R, Greally P, Slattery D, Daly L, Durie P, Bourke B. Outcome in cystic fibrosis liver disease. Am J Gastroenterol 2011;106:104-9. [PMID: 20736939 DOI: 10.1038/ajg.2010.316] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
5 de Monestrol I, Klint Å, Sparén P, Hjelte L. Age at diagnosis and disease progression of cystic fibrosis in an area without newborn screening: Age at diagnosis of cystic fibrosis. Paediatric and Perinatal Epidemiology 2011;25:298-305. [DOI: 10.1111/j.1365-3016.2010.01162.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sasame A, Stokes D, Bourke B, Connolly L, Fitzpatrick E, Rowland M. The impact of liver disease on mortality in cystic fibrosis-A systematic review. J Cyst Fibros 2021:S1569-1993(21)01328-X. [PMID: 34380590 DOI: 10.1016/j.jcf.2021.07.014] [Reference Citation Analysis]
7 Walshaw M. Routine OGTT screening for CFRD - no thanks. J R Soc Med 2009;102 Suppl 1:40-4. [PMID: 19605874 DOI: 10.1258/jrsm.2009.s19009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
8 Gridelli B. Benefit of liver transplantation in patients with cystic fibrosis. Nat Rev Gastroenterol Hepatol 2011;8:187-8. [DOI: 10.1038/nrgastro.2011.39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Van Biervliet S, Verdievel H, Vande Velde S, De Bruyne R, De Looze D, Verhelst X, Geerts A, Robberecht E, Van Vlierberghe H. Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. Ultrasound in Medicine & Biology 2016;42:848-54. [DOI: 10.1016/j.ultrasmedbio.2015.11.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
10 Karlas T, Neuschulz M, Oltmanns A, Güttler A, Petroff D, Wirtz H, Mainz JG, Mössner J, Berg T, Tröltzsch M, Keim V, Wiegand J. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One 2012;7:e42139. [PMID: 22848732 DOI: 10.1371/journal.pone.0042139] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
11 Klotter V, Gunchick C, Siemers E, Rath T, Hudel H, Naehrlich L, Roderfeld M, Roeb E. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS One 2017;12:e0178784. [PMID: 28575039 DOI: 10.1371/journal.pone.0178784] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bodewes FAJA, Wouthuyzen-bakker M, Bijvelds MJ, Havinga R, de Jonge HR, Verkade HJ. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator ( Cftr ) in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012;302:G1035-42. [DOI: 10.1152/ajpgi.00258.2011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Rowland M, Bourke B. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2011;17:461-6. [PMID: 21881510 DOI: 10.1097/MCP.0b013e32834b7f51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Morrell MR, Pilewski JM. Lung Transplantation for Cystic Fibrosis. Clinics in Chest Medicine 2016;37:127-38. [DOI: 10.1016/j.ccm.2015.11.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
15 Joly P, Restier L, Bouchecareilh M, Lacan P, Cabet F, Chapuis-cellier C, Francina A, Lachaux A. Cohorte DEFI-ALPHA et projet hospitalier de recherche clinique POLYGEN DEFI-ALPHA. Étude des facteurs cliniques, biologiques et génétiques associés à l’apparition et à l’évolution de complications hépatiques chez les enfants présentant un déficit en alpha-1 antitrypsine. Revue des Maladies Respiratoires 2015;32:759-67. [DOI: 10.1016/j.rmr.2015.06.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Drzymała-Czyż S, Dziedzic K, Szwengiel A, Krzyżanowska-Jankowska P, Nowak JK, Nowicka A, Aringazina R, Drzymała S, Kashirskaya N, Walkowiak J. Serum bile acids in cystic fibrosis patients-glycodeoxycholic acid as a potential marker of liver disease. Dig Liver Dis 2021:S1590-8658(21)00370-4. [PMID: 34305015 DOI: 10.1016/j.dld.2021.06.034] [Reference Citation Analysis]
17 Kotb MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914. [PMID: 22942741 DOI: 10.3390/ijms13078882] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
18 Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol 2017;2017:5128760. [PMID: 28250993 DOI: 10.1155/2017/5128760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
19 Bodewes FA, van der Doef HP, Houwen RH, Verkade HJ. Increase of Serum γ-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;61:113-8. [DOI: 10.1097/mpg.0000000000000758] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
20 Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry: Pulmonary Function in Individuals with Cystic Fibrosis. Liver Transpl 2012;18:585-93. [DOI: 10.1002/lt.23389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
21 Messick J. A 21st-century approach to cystic fibrosis: optimizing outcomes across the disease spectrum. J Pediatr Gastroenterol Nutr 2010;51 Suppl 7:S1-7; quiz 3 p following S7. [PMID: 20739870 DOI: 10.1097/MPG.0b013e3181ec0242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Bodewes FA, Bijvelds MJ, de Vries W, Baller JF, Gouw AS, de Jonge HR, Verkade HJ. Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice. PLoS One 2015;10:e0117599. [PMID: 25680200 DOI: 10.1371/journal.pone.0117599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
23 Karlas T, Neuschulz M, Oltmanns A, Wirtz H, Keim V, Wiegand J. ARFI and transient elastography for characterization of cystic fibrosis related liver disease: first longitudinal follow-up data in adult patients. J Cyst Fibros. 2013;12:826-827. [PMID: 23628512 DOI: 10.1016/j.jcf.2013.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
24 Mayer-Hamblett N, Kloster M, Ramsey BW, Narkewicz MR, Saiman L, Goss CH. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials 2013;34:232-8. [PMID: 23200843 DOI: 10.1016/j.cct.2012.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
25 Pals F, Verkade H, Gulmans V, De Koning B, Koot B, De Meij T, Hendriks D, Gierenz N, Vreugdenhil A, Houwen R, Bodewes F. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands. Journal of Cystic Fibrosis 2019;18:385-9. [DOI: 10.1016/j.jcf.2018.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
26 Cemlyn-jones J, Gamboa F. Proteinuria in cystic fibrosis: a possible correlation between genotype and renal phenotype. J bras pneumol 2009;35:669-75. [DOI: 10.1590/s1806-37132009000700008] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
27 Lu BR, Esquivel CO. A review of abdominal organ transplantation in cystic fibrosis. Pediatr Transplant 2010;14:954-60. [PMID: 20946451 DOI: 10.1111/j.1399-3046.2010.01412.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
28 Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
29 Andrieux A, Harambat J, Bui S, Nacka F, Iron A, Llanas B, Fayon M. Renal impairment in children with cystic fibrosis. J Cyst Fibros 2010;9:263-8. [PMID: 20413352 DOI: 10.1016/j.jcf.2010.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
30 Lemaitre C, Dominique S, Billoud E, Eliezer M, Montialoux H, Quillard M, Riachi G, Koning E, Morisse-Pradier H, Savoye G. Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease? Can Respir J. 2016;2016:4592702. [PMID: 27445541 DOI: 10.1155/2016/4592702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
31 Rowland M, Gallagher C, Gallagher CG, Laoide RÓ, Canny G, Broderick AM, Drummond J, Greally P, Slattery D, Daly L, McElvaney NG, Bourke B. Outcome in patients with cystic fibrosis liver disease. J Cyst Fibros 2015;14:120-6. [PMID: 24917116 DOI: 10.1016/j.jcf.2014.05.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
32 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
33 O'neil DA, Fraser-pitt D. Progress towards next-generation therapeutics for cystic fibrosis. Future Medicinal Chemistry 2014;6:1067-79. [DOI: 10.4155/fmc.14.67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Chryssostalis A, Hubert D, Coste J, Kanaan R, Burgel PR, Desmazes-Dufeu N, Soubrane O, Dusser D, Sogni P. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol 2011;55:1377-82. [PMID: 21703187 DOI: 10.1016/j.jhep.2011.03.028] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
35 Drzymała-czyż S, Jończyk-potoczna K, Lisowska A, Stajgis M, Walkowiak J. Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement: . European Journal of Gastroenterology & Hepatology 2016;28:645-9. [DOI: 10.1097/meg.0000000000000593] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Cipolli M, Fethney J, Waters D, Zanolla L, Meneghelli I, Dutt S, Assael BM, Gaskin KJ. Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study. Journal of Cystic Fibrosis 2020;19:455-9. [DOI: 10.1016/j.jcf.2019.09.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T. Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology. 2017;66:591-601. [PMID: 28422310 DOI: 10.1002/hep.29217] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
38 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017;46:e125-38. [PMID: 28554721 DOI: 10.1016/j.lpm.2017.05.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
39 Drzymała-Czyż S, Krzyżanowska-Jankowska P, Dziedzic K, Lisowska A, Kurek S, Goździk-Spychalska J, Kononets V, Woźniak D, Mądry E, Walkowiak J. Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis. Biomolecules 2021;11:313. [PMID: 33669566 DOI: 10.3390/biom11020313] [Reference Citation Analysis]
40 Drzymała-czyż S, Szczepanik M, Krzyżanowska P, Duś-żuchowska M, Pogorzelski A, Sapiejka E, Juszczak P, Lisowska A, Koletzko B, Walkowiak J. Serum Phospholipid Fatty Acid Composition in Cystic Fibrosis Patients with and without Liver Cirrhosis. Ann Nutr Metab 2017;71:91-8. [DOI: 10.1159/000477913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
41 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]